Effect of edaravone against consciousness impairment after encephalitis

Effect of edaravone against consciousness impairment after encephalitis - Effect of edaravone against consciousness impairment after encephalitis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010052

Enrollment

Registered

2013-02-15

Start date

2013-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Limbic encephalitis

Interventions

injection of edaravone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diagnosed with limbic encephalitis patients who had obtained consent from the person or family.

Exclusion criteria

Exclusion criteria: 1.male:Cre<1.3 mg/dl Female:Cre<1.0 mg/dl male & femaile:AST/ALT<more than three times the reference value 2.sepsis 3.epilepticus and severe coma 4.bacterial meningitis and encephalitis 5.DIC 6.allergy for edaravone 7. edaravone is used within two weeks prior to registration 8.acute cereberal infarction 9.Patients within 6 months after the end of the other trial 10.investigator has determined the patient disqualified as a target

Design outcomes

Primary

Measure	Time frame
improvement of Glasgow coma scale	—

Secondary

Measure	Time frame
Japan coma scale, HDSR,MMSE,Barthel index	—

Countries

Japan

Contacts

Public ContactAkiko Ishii

University of Tsukuba Neurology

neurol@md.tsukuba.ac.jp029-853-3224

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026